08/07/2011 00:00AM Australia/Sydney
BRACKNELL, United Kingdom (BUSINESS WIRE)
Dedicated Clinical Research Facility Unveiled
Quintiles today reached a significant milestone in its prime site
program with the official opening of a clinical research facility within
Queen Mary, University of London.
Queen Mary was Quintiles’ first prime site, with the collaboration
dating back to 2007. Prime Sites are large clinical institutions that
collaborate with Quintiles to drive productivity and excellence in
clinical research. Quintiles provides dedicated resources to the
clinical research facility to maximize patient recruitment and
“In the New Health, there is significant pressure to speed the
drug development process in order to develop treatments that enable
people to live healthier lives,” said Lindy Jones, Global Head of
Integrated Site Services. “We are proud to be working with the team at
Queen Mary to further enhance our ability to recruit patients and
investigators who are critical to an efficient and effective drug
Since 2008 the site has consistently delivered a significant proportion
of the patients enrolled in the UK and enrollment numbers are ahead of
other sites around the globe. In 2011 to date the site has recruited
more than 10 percent of UK patients enrolled in Quintiles studies.
Investigators at Queen Mary work on at least 20 studies at any one time,
across multiple therapeutic areas, with best in class start-up timelines.
Mark Caulfield, Director of William Harvey Research Institute and The
NIHR Cardiovascular Biomedical Research Unit at Queen Mary, said:
“We are delighted to be working with Quintiles who, like ourselves have
the patient at the heart of everything they do. This center will enhance
collaboration between medical and clinical research professionals and
academics across a range of protocols and therapeutic areas.
“Quintiles was one of six donors to the center, which aims to provide a
research pipeline whereby the innovation of new therapeutics can be
converted from laboratory to patient in one unique environment.”
This investment by Quintiles follows the opening of an expanded
Phase I clinical research facility in Guy’s Hospital Tower in 2010,
and a Central
Laboratory and office facility in Edinburgh in 2009.
Quintiles is the only fully integrated biopharmaceutical services
company offering clinical, commercial, consulting and capital solutions
worldwide. The Quintiles network of more than 20,000 engaged
professionals in 60 countries works with an unwavering commitment to
patients, safety and ethics. Quintiles helps biopharmaceutical companies
navigate risk and seize opportunities in an environment where change is
constant. For more information, please visit www.quintiles.com.